129 related articles for article (PubMed ID: 11467831)
21. Ha-ras-transformation alters the metabolism of phosphatidylethanolamine and phosphatidylcholine in NIH 3T3 fibroblasts.
Momchilova A; Markovska T; Pankov R
Cell Biol Int; 1999; 23(9):603-10. PubMed ID: 10728571
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism.
Rodríguez-González A; Ramírez de Molina A; Bañez-Coronel M; Megias D; Lacal JC
Int J Oncol; 2005 Apr; 26(4):999-1008. PubMed ID: 15753995
[TBL] [Abstract][Full Text] [Related]
23. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
[TBL] [Abstract][Full Text] [Related]
24. R-Ras promotes tumor growth of cervical epithelial cells.
Rincón-Arano H; Rosales R; Mora N; Rodriguez-Castañeda A; Rosales C
Cancer; 2003 Feb; 97(3):575-85. PubMed ID: 12548599
[TBL] [Abstract][Full Text] [Related]
25. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2.
Fehrenbacher N; Bastholm L; Kirkegaard-Sørensen T; Rafn B; Bøttzauw T; Nielsen C; Weber E; Shirasawa S; Kallunki T; Jäättelä M
Cancer Res; 2008 Aug; 68(16):6623-33. PubMed ID: 18701486
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors.
Rubio-Ruíz B; Conejo-García A; Ríos-Marco P; Carrasco-Jiménez MP; Segovia J; Marco C; Gallo MA; Espinosa A; Entrena A
Eur J Med Chem; 2012 Apr; 50():154-62. PubMed ID: 22348828
[TBL] [Abstract][Full Text] [Related]
27. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
28. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
Campos J; Núñez MC; Conejo-García A; Sánchez-Martín RM; Hernández-Alcoceba R; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
Curr Med Chem; 2003 Jul; 10(13):1095-112. PubMed ID: 12678804
[TBL] [Abstract][Full Text] [Related]
29. Novel 4-amino bis-pyridinium and bis-quinolinium derivatives as choline kinase inhibitors with antiproliferative activity against the human breast cancer SKBR-3 cell line.
Gómez-Pérez V; McSorley T; See Too WC; Konrad M; Campos JM
ChemMedChem; 2012 Apr; 7(4):663-9. PubMed ID: 22278967
[TBL] [Abstract][Full Text] [Related]
30. Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells.
Cheng G; Meinkoth JL
Oncogene; 2001 Nov; 20(50):7334-41. PubMed ID: 11704863
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
32. Anticancer bisquaternary heterocyclic compounds: a ras-ional design.
Campos J; Núñez C; Díaz JJ; Sánchez RM; Gallo MA; Espinosa A
Farmaco; 2003 Mar; 58(3):221-9. PubMed ID: 12620418
[TBL] [Abstract][Full Text] [Related]
33. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
Jiang K; Delarue FL; Sebti SM
Oncogene; 2004 Feb; 23(5):1136-45. PubMed ID: 14647415
[TBL] [Abstract][Full Text] [Related]
34. [Constitutive activity of MAP kinase cascades in REF cells transformed by E1A and cHa-ras oncogenes].
Svetlikova SB; Abramova MV; Kukushkin AN; Darieva ZA; Pospelova TV; Pospelov VA
Tsitologiia; 2001; 43(10):961-8. PubMed ID: 11769129
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules.
Wasylyk C; Zheng H; Castell C; Debussche L; Multon MC; Wasylyk B
Cancer Res; 2008 Mar; 68(5):1275-83. PubMed ID: 18316589
[TBL] [Abstract][Full Text] [Related]
36. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
Kim HS; Kim JW; Gang J; Wen J; Koh SS; Koh JS; Chung HH; Song SY
Toxicol Appl Pharmacol; 2006 Sep; 215(3):317-29. PubMed ID: 16712893
[TBL] [Abstract][Full Text] [Related]
37. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
38. A novel 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol with antitumoral activity via cell cycle arrest and induction of apoptosis.
Báñez-Coronel M; Rodríguez-González A; Martín-Cantalejo Y; Sáez B; Soto J; Villa MJ; Braña MF; Lacal JC
Int J Oncol; 2004 Oct; 25(4):1097-103. PubMed ID: 15375561
[TBL] [Abstract][Full Text] [Related]
39. c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1.
Nielsen C; Thastrup J; Bøttzauw T; Jäättelä M; Kallunki T
Cancer Res; 2007 Jan; 67(1):178-85. PubMed ID: 17210697
[TBL] [Abstract][Full Text] [Related]
40. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
Xin H; Geng Y; Pramanik R; Choubey D
J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
